Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 9 of 9 for “"Velcade"”.

  1. Mechanisms Underlying The Heterogeneous Sensitivities of Cancer Cells to Proteasome Inhibitors

    … FDA-approved proteasome inhibitor bortezomib (Velcade®) in solid tumor cells, we demonstrated that perhaps the most critical response to proteasome inhibition is repression of global protein synthesis by phosphorylation of the eukaryotic initiation factor 2-α subunit (eIF2α). In a panel of 10 …

    uthsc Repository record for Mechanisms Underlying The Heterogeneous Sensitivities of Cancer Cells to Proteasome Inhibitors (opens in a new tab)

  2. Synergy and Resistance Mechanisms in R115777 and PS-341 Models of Myeloma and Leukemia

    … antitumor agents including PS-341 (Bortezomib, Velcade). Comparison of gene expression profiles between resistant and sensitive cells revealed expression changes in several genes involved in myeloma survival and drug resistance. Identification and characterization of the 8226/R5 cell line helped …

    usf Repository record for Synergy and Resistance Mechanisms in R115777 and PS-341 Models of Myeloma and Leukemia (opens in a new tab)

  3. The Role of Fatty Acid Elongase ELOVL6 in Multiple Myeloma Drug Resistance

    … with the introduction of Bortezomib (BTZ, Velcade), a novel first generation proteasome inhibitor, MM patients survival rates have improved remarkably. Unfortunately, rapidly developing drug resistance has been detrimental for the success of BTZ treatment. It has been concluded that BTZ …

    buffalo Repository record for The Role of Fatty Acid Elongase ELOVL6 in Multiple Myeloma Drug Resistance (opens in a new tab)

  4. Development of Transition Metal-Catalyzed Borylation Protocols using Symmetrical and Unsymmetrical Diboron Reagents

    … applications since the FDA approval of Velcade©. As a result, transition metal-catalyzed protocols to incorporate boron reagents into unsaturated compounds have been extensively researched. While an abundance of literature protocols have been reported, the majority utilize harsh reaction …

    vt Repository record for Development of Transition Metal-Catalyzed Borylation Protocols using Symmetrical and Unsymmetrical Diboron Reagents (opens in a new tab)

  5. Neurochemical characterization of primary sensory neurons in a rat model of bortezomic-induced peripheral neuropathy

    … newer agents such as bortezomib. Bortezomib (VELCADE) is a boronic acid dipeptide, which causes a selective blockade of proteasome activity. Bortezomib-induced peripheral neuropathy is an important clinical complication, often difficult to manage or reverse, whose treatment usually involves …

    cagliari Repository record for Neurochemical characterization of primary sensory neurons in a rat model of bortezomic-induced peripheral neuropathy (opens in a new tab)

  6. Inhibition RANKL-induzierter Differenzierung und Aktivierung humaner Osteoklasten durch MG-132, MG-262, Bortezomib und Curcumin

    … MG-132, MG-262 und Bortezomib (PS-341, VELCADE®) sowie Curcumin. Zur Gewinnung humaner Präosteoklasten und Osteoklasten wurde gesunden Probanden peripheres Venenblut entnommen, aus dem die Selektion möglicher Osteoklastenvorläuferzellen innerhalb der Monozyten-Makrophagen-Linie erfolgte. …

    fu-berlin Repository record for Inhibition RANKL-induzierter Differenzierung und Aktivierung humaner Osteoklasten durch MG-132, MG-262, Bortezomib und Curcumin (opens in a new tab)

  7. Multiple Myeloma and Its Treatment Alter Peripheral Nervous System Structure and Function

    … treatment. Proteasome inhibitor, bortezomib (Velcade®) is an effective treatment of multiple myeloma (MM), but often provokes the development of small fiber, sensory, distal neuropathy in patients. MM is caused by malignancy of plasma cells, which indirectly compromises multiple organ systems. …

    uthsc Repository record for Multiple Myeloma and Its Treatment Alter Peripheral Nervous System Structure and Function (opens in a new tab)

  8. Pre-Clinical Assessment of the Proteasomal Inhibitor Bortezomib as a Generalized Therapeutic Approach for Recessively Inherited Disorders

    The number of known monogenic rare diseases (~7000) exceeds the number of effective treatments (~500) by more than an order of magnitude underlining the pressing need for generalizable therapeutic approaches for this class of conditions. In this regard, the majority of recessive and x-linked …

    ottawa-retro Repository record for Pre-Clinical Assessment of the Proteasomal Inhibitor Bortezomib as a Generalized Therapeutic Approach for Recessively Inherited Disorders (opens in a new tab)